Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus raltitrexed versus irinotecan salvage chemotherapy for advanced esophageal squamous cell carcinoma
ChiCTR1900027159Phase 2Recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan and raltitrexed in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Yancheng First People's Hospital. Primary endpoints: progression-free survival and overall survival. Started Nov 2019; status: recruiting.
02
Drugs
irinotecanraltitrexed
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900027159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027159.